Safety Study of Tivanisiran to Treat Dry Eye
Public ClinicalTrials.gov record NCT05310422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT05310422
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sylentis, S.A.
- Industry
- Enrollment
- 301 participants
Conditions and interventions
Conditions
Interventions
- Tivanisiran sodium ophthalmic solution Drug
- Vehicle ophthalmic solution Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2022
- Primary completion
- Oct 10, 2023
- Completion
- Oct 10, 2023
- Last update posted
- Feb 19, 2024
2022 – 2023
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sylentis Investigative Site | Chandler | Arizona | 85021 | — |
| Sylentis Investigative Site | Phoenix | Arizona | 85032 | — |
| FYDES Investigative Site | Glendale | California | 91204 | — |
| Sylentis Investigative Site | Hemet | California | 92545 | — |
| Sylentis Investigative Site | Los Angeles | California | 85032 | — |
| Sylentis Investigative Site | Murrieta | California | 92562 | — |
| Sylentis Investigative Site | Newport Beach | California | 92663 | — |
| FYDES Investigative Site | Delray Beach | Florida | 33484 | — |
| FYDES Investigative Site | Jacksonville | Florida | 32256 | — |
| Sylentis Investigative Site | Largo | Florida | 33773 | — |
| Sylentis Investigative Site | Morrow | Georgia | 30260 | — |
| Sylentis Investigative Site | Fraser | Michigan | 48026 | — |
| Sylentis Investigative Site | Kansas City | Missouri | 64111 | — |
| FYDES Investigative Site | St Louis | Missouri | 63131 | — |
| Sylentis Investigative Site | Washington | Missouri | 63090 | — |
| Sylentis Investigative Site | Rochester | New York | 14618 | — |
| Sylentis Investigative Site | Asheville | North Carolina | 28803 | — |
| Sylentis Investigative Site | Garner | North Carolina | 27529 | — |
| Sylentis Investigative Site | Cranberry Township | Pennsylvania | 16066 | — |
| Sylentis Investigative Site | Rapid City | South Dakota | 57701 | — |
| Sylentis Investigative Site | Memphis | Tennessee | 38119 | — |
| Sylentis Investigative Site | Austin | Texas | 78731 | — |
| FYDES Investigative Site | El Paso | Texas | 79902 | — |
| Sylentis Investigative Site | San Antonio | Texas | 78215 | — |
| Sylentis Investigative Site | San Antonio | Texas | 78230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05310422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05310422 live on ClinicalTrials.gov.